DiaGenic ASA Provides Study Results and Update on Key Clinical Programs
10/10/2013 11:26:15 AM
OSLO, Norway--(BUSINESS WIRE)--Regulatory News: DiaGenic (OSE:DIAG) announces results from the calibration study for MCItect®, a blood based diagnostic test for Alzheimer’s disease in the pre-dementia stage. In a patient population of 157 patients diagnosed with amnestic mild cognitive impairment, MCItect® demonstrated a total prediction accuracy of 75% in detecting patients converting to Alzheimer’s disease dementia within two years. The study included 157 patients from 19 centers in Europe and the U.S. diagnosed with amnestic mild cognitive impairment, MCI, that either remained stable or progressed to Alzheimer’s disease dementia during a two-year period. The primary goal of the study was to verify a gene expression test that predicts which patients remain stable and which progress to Alzheimer’s disease dementia within two years, based on a larger and more ethnically diverse patient population. The total prediction accuracy of this enhanced version of MCItect® was 75%, with 75% sensitivity and 73% specificity. This result is based on the total study population, including sixteen statistical outliers of which at least six were considered potentially misdiagnosed.
Help employers find you! Check out all the jobs and post your resume.
comments powered by